EPO Dosing in Chronic Kidney Disease

Introduction to EPO Dosing

The American College of Cardiology and other guideline societies recommend initiating erythropoietin at 80-120 units/kg/week subcutaneously or 120-180 units/kg/week intravenously for hemodialysis patients, targeting a hemoglobin of 110 g/L with an acceptable range of 100-120 g/L 1, 2

Start ESAs only after correcting iron stores and treating other reversible causes of anemia, when hemoglobin is sustained below 100 g/L 2
Ensure adequate iron supplementation throughout treatment, as iron deficiency is the most common cause of inadequate ESA response 3, 4

Target hemoglobin of 110 g/L with acceptable range 100-120 g/L 2
Never target hemoglobin above 120 g/L, as this increases cardiovascular mortality and adverse events without improving quality of life 2, 5
The CHOIR trial demonstrated that targeting hemoglobin of 135 g/L versus 113 g/L resulted in 34% increased risk of death, MI, CHF hospitalization, or stroke (HR 1.34, p=0.03) 5

Subcutaneous administration is preferred for most patients, with a dose of 80-120 units/kg/week divided into 2-3 doses per week 1
Intravenous administration is recommended for hemodialysis patients, with a dose of 120-180 units/kg/week divided into 3 doses 1

Goal is to achieve target hemoglobin within 2-4 months through slow, steady increases 1, 4
Monitor hemoglobin every 1-2 weeks after initiation or dose changes 6, 1
Expected hemoglobin increase with adequate iron: approximately 0.3 g/dL per week 3

Higher ESA doses independently increase mortality risk beyond hemoglobin effects 6
Blood pressure elevation requiring increased antihypertensive therapy 6
Hemodialysis access thrombosis (increases with higher hemoglobin targets) 6
Risk of hypertension and seizures with rapid hemoglobin rise 6

Do not use ESAs without first ensuring adequate iron stores - check transferrin saturation and ferritin before and during treatment 2, 3, 4
Do not target "normal" hemoglobin levels - this increases cardiovascular risk and mortality 2, 5
Do not dose IV epoetin less than three times weekly - this requires 25% higher doses 3

Hemodialysis patients with cardiovascular disease require particular caution, as the Besarab trial showed increased mortality when targeting hemoglobin 140 g/L versus 100 g/L in HD patients with CHF or ischemic heart disease 5
Pediatric patients, especially those under 5 years, may require higher doses than older children 4

For a typical 70 kg adult with chronic kidney disease, the American Journal of Kidney Diseases recommends starting with 3,500-7,000 units of Epogen three times weekly subcutaneously 7, 8
The subcutaneous route is preferred as it requires 15-50% less total dose compared to IV administration, according to the American Journal of Kidney Diseases 7, 8
Divide the weekly dose into 2-3 administrations per week for optimal efficiency, as suggested by the American Journal of Kidney Diseases 7, 8
For cancer patients on chemotherapy, the National Comprehensive Cancer Network recommends 40,000 units weekly or 150 units/kg three times weekly subcutaneously 9

The American Journal of Kidney Diseases suggests measuring hemoglobin every 1-2 weeks after initiation or dose changes, and adjusting the dose accordingly to achieve a target hemoglobin of 11-12 g/dL 7, 8
If hemoglobin increases <1 g/dL over 2-4 weeks, increase the dose by 50%, and if hemoglobin increases ≥1 g/dL over 2 weeks, reduce the dose by 25-40% 7, 8

When switching from IV to subcutaneous administration, start with two-thirds of the weekly IV dose if the target hemoglobin is already achieved, as recommended by the American Journal of Kidney Diseases 7, 8
Once the target hemoglobin is achieved, extended dosing intervals of once weekly or every 2 weeks may be considered for convenience, but may require higher total doses, according to the American Journal of Kidney Diseases 7, 8